Optimal Inhalation Therapy for Chronic Obstructive Pulmonary Disease(COPD) Patients

• Status: Not yet recruiting
• Trial end date: 2024-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of the study is to examine whether long-acting muscarinic antagonist (LAMA) administration at bedtime versus in the morning leads to a reduction in severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) among COPD-patients who are already receiving treatment with LAMAs. The hypothesis is that bedtime administration of LAMA, as opposed to morning administration, will lead to fewer severe AECOPD exacerbations. Further, bedtime administration of LAMA will lead to fewer moderate AECOPD´s, fewer cases where non-invasive ventilation (NIV) is needed and a lower mortality in COPD patients who are already using LAMAs.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chronic Obstructive Pulmonary Disease Trial Network, Denmark
• Treatments: Cholinergic Agents; Muscarinic Antagonists

Criteria

Inclusion Criteria:

1. Age more than or equal to 30 years

2. Current treatment with LAMA (as recorded in the Danish National Prescription Registry and confirmed by the participant via questionnaire)

Exclusion Criteria:

1. Patients who declined to participate.

2. Patients receiving LAMA treatment more than once daily